Jon Amund Kyte (J A Kyte)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 22

Top Topics

Positive Breast Cancer

Locally Advanced

Top Venues

Journal for immunotherapy of cancer

International journal of molecular sciences

NPJ breast cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Claire Quaghebeur, Bjørnar Gilje, Beate Boge, Andrea Gombos, Ragnhild Sørum Falk, Randi R Mathiesen, Lars Julsrud, Øystein Garred, Hege G Russnes, Ragnhild Reehorst Lereim, Sudhir Kumar Chauhan, Ole Christian Lingjærde, Claire Dunn, Bjørn Naume, Jon Amund Kyte
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial. Journal for immunotherapy of cancer 12 (1) (2024)
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Claire Quaghebeur, Bjørnar Gilje, Beate Boge, Andrea Gombos, Ragnhild Sørum Falk, Randi R Mathiesen, Lars Julsrud, Øystein Garred, Hege G Russnes, Ragnhild Reehorst Lereim, Sudhir Kumar Chauhan, Ole Christian Lingjærde, Claire Dunn, Bjørn Naume, Jon Amund Kyte
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial. Journal for immunotherapy of cancer 12 (1) (2024)
Yixin Jin, Claire Dunn, Irene Persiconi, Adam Sike, Gjertrud Skorstad, Carole Beck, Jon Amund Kyte
Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers. International journal of molecular sciences 25 (1) (2024)
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Claire Quaghebeur, Bjørnar Gilje, Beate Boge, Andrea Gombos, Ragnhild Sørum Falk, Randi R Mathiesen, Lars Julsrud, Øystein Garred, Hege G Russnes, Ragnhild Reehorst Lereim, Sudhir Kumar Chauhan, Ole Christian Lingjærde, Claire Dunn, Bjørn Naume, Jon Amund Kyte
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial. Journal for immunotherapy of cancer 12 (1) (2024)
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen, Cecilie Bendigtsen Schirmer, Bjørnar Gilje, Øystein Garred, Jon Lømo, Marius Stensland, Oddmund Nordgård, Ragnhild Sørum Falk, Randi R Mathiesen, Hege G Russnes, Jon Amund Kyte, Bjørn Naume
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials. Molecular oncology (2024)
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Claire Quaghebeur, Bjørnar Gilje, Beate Boge, Andrea Gombos, Ragnhild Sørum Falk, Randi R Mathiesen, Lars Julsrud, Øystein Garred, Hege G Russnes, Ragnhild Reehorst Lereim, Sudhir Kumar Chauhan, Ole Christian Lingjærde, Claire Dunn, Bjørn Naume, Jon Amund Kyte
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial. Journal for immunotherapy of cancer 12 (1) (2024)
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Claire Quaghebeur, Bjørnar Gilje, Beate Boge, Andrea Gombos, Ragnhild Sørum Falk, Randi R Mathiesen, Lars Julsrud, Øystein Garred, Hege G Russnes, Ragnhild Reehorst Lereim, Sudhir Kumar Chauhan, Ole Christian Lingjærde, Claire Dunn, Bjørn Naume, Jon Amund Kyte
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial. Journal for immunotherapy of cancer 12 (1) (2024)
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Claire Quaghebeur, Bjørnar Gilje, Beate Boge, Andrea Gombos, Ragnhild Sørum Falk, Randi R Mathiesen, Lars Julsrud, Øystein Garred, Hege G Russnes, Ragnhild Reehorst Lereim, Sudhir Kumar Chauhan, Ole Christian Lingjærde, Claire Dunn, Bjørn Naume, Jon Amund Kyte
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial. Journal for immunotherapy of cancer 12 (1) (2024)
Yixin Jin, Claire Dunn, Irene Persiconi, Adam Sike, Gjertrud Skorstad, Carole Beck, Jon Amund Kyte
Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers. International journal of molecular sciences 25 (1) (2024)
Yixin Jin, Claire Dunn, Irene Persiconi, Adam Sike, Gjertrud Skorstad, Carole Beck, Jon Amund Kyte
Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers. International journal of molecular sciences 25 (1) (2024)
Sudhir Kumar Chauhan, Claire Dunn, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Gjertrud Skorstad, Adam Sike, Bjørnar Gilje, Sunil Xavier Raj, Kanutte Huse, Bjørn Naume, Jon Amund Kyte
Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation. NPJ breast cancer 10 (1) (2024)
Yixin Jin, Claire Dunn, Irene Persiconi, Adam Sike, Gjertrud Skorstad, Carole Beck, Jon Amund Kyte
Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers. International journal of molecular sciences 25 (1) (2024)
Sudhir Kumar Chauhan, Claire Dunn, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Gjertrud Skorstad, Adam Sike, Bjørnar Gilje, Sunil Xavier Raj, Kanutte Huse, Bjørn Naume, Jon Amund Kyte
Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation. NPJ breast cancer 10 (1) (2024)
Sudhir Kumar Chauhan, Claire Dunn, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Gjertrud Skorstad, Adam Sike, Bjørnar Gilje, Sunil Xavier Raj, Kanutte Huse, Bjørn Naume, Jon Amund Kyte
Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation. NPJ breast cancer 10 (1) (2024)
Carole Beck, Nicholas Paul Casey, Irene Persiconi, Neda Nejati Moharrami, Adam Sike, Yixin Jin, Jon Amund Kyte
Development of a TGFβ-IL-2/15 Switch Receptor for Use in Adoptive Cell Therapy. Biomedicines 11 (2) (2023)
Carole Beck, Nicholas Paul Casey, Irene Persiconi, Neda Nejati Moharrami, Adam Sike, Yixin Jin, Jon Amund Kyte
Development of a TGFβ-IL-2/15 Switch Receptor for Use in Adoptive Cell Therapy. Biomedicines 11 (2) (2023)
Jon Amund Kyte
Strategies for Improving the Efficacy of CAR T Cells in Solid Cancers. Cancers 14 (3) (2022)
Andreas Hagen Røssevold, Nikolai Kragøe Andresen, Christina Annette Bjerre, Bjørnar Gilje, Erik Hugger Jakobsen, Sunil Xavier Raj, Ragnhild Sørum Falk, Hege Giercksky Russnes, Thea Jahr, Randi Ruud Mathiesen, Jon Lømo, Øystein Garred, Sudhir Kumar Chauhan, Ragnhild Reehorst Lereim, Claire Dunn, Bjørn Naume, Jon Amund Kyte
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial. Nature medicine (2022)
S Esmaeil Dorraji, Elin Borgen, Dario Segura-Peña, Puneet Rawat, Eva Smorodina, Claire Dunn, Victor Greiff, Nikolina Sekulić, Hege Russnes, Jon Amund Kyte
Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform. Cancers 14 (19) (2022)
Jon Amund Kyte, N K Andresen, H G Russnes, S Ø Fretland, R S Falk, O C Lingjærde, B Naume
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer. Journal of translational medicine 18 (1) (2020)
Jon Amund Kyte, A Røssevold, R S Falk, B Naume
ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer. Journal of translational medicine 18 (1) (2020)
Jon Amund Kyte, Anne Fåne, Martin Pule, Gustav Gaudernack
Transient redirection of T cells for adoptive cell therapy with telomerase-specific T helper cell receptors isolated from long term survivors after cancer vaccination. Oncoimmunology 8 (4) (2019)